All In Biotech

Drug Trial Radar · NCT06702995

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

A Phase Ib/II Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Failed Prior Novel Hormone Therapy

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

307

Planned (sponsor's estimate)

Start

Apr 19, 2023

Primary completion

Jul 13, 2027

Study completion Jul 13, 2027

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.

Conditions

  • Metastatic Castrate-Resistant Prostate Cancer
  • mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

  • XNW5004Drug

    Oral continuous

  • enzalutamideDrug

    enzalutamide 160 mg (four 40 mg capsules) orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ph Ib/IIa: Overall safety profile including adverse eventsTime frame: Baseline up to approximately 2 years
  2. Ph Ib/IIa: Recommended phase 2 doses (RP2D) of XNW5004 in combination with enzalutamideTime frame: Approximately 6 months
  3. Preliminary efficacy determination as evaluated by disease specific response criteriaTime frame: Baseline until disease progression or death or through study completion (approximately 2 years)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province

    Jinan, Shandong, China · Recruiting

  • 270 Dongan Road, Shanghai

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.